Pharmaust Limited (ASX:PAA)
Pharmaust Limited is an Australia-based clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for cancer, neurodegenerative diseases and viral infections in humans and cancer for pet dogs. The Company's lead candidate, monepantel (MPL), is a small molecule drug primarily being developed as a safe and potent treatment for cancer. The MPL can also be used for neurodegenerative diseases such as Motor Neuron Disease, Parkinson's Disease, and Alzheimer's Disease. It has completed Phase I clinical trials with MPL in humans and dogs diagnosed with solid tumors. The Company has also initiated a preclinical program to screen its portfolio of aminoacetonitrile (AAD) compounds for anticancer activity.